Recurv is a U.S.-based special purpose biotechnology company created to develop to clinical proof-of-concept one oncology compound, RP-001, a novel taxane therapy to treat solid tumors.
The project is fully financed by TVM Life Science Innovation II. In various pre-clinical oncology models, the asset has shown strong efficacy data in addition to a potentially superior safety profile
compared to currently available taxanes, as well as synergistic effects with immune checkpoint inhibitors.
James E. Egan (CEO)